- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04396860
Testowanie stosowania leków immunoterapeutycznych Ipilimumab i Nivolumab Plus Radioterapia w porównaniu ze zwykłym leczeniem (temozolomidem i radioterapią) w przypadku nowo rozpoznanego glejaka niemetylowanego MGMT
Randomizowane badanie otwarte fazy II/III porównujące ipilimumab i niwolumab w porównaniu z temozolomidem u pacjentów z nowo rozpoznanym MGMT (metylotransferaza DNA O-6-metyloguaniny guza) niemetylowanym glejakiem
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
Przegląd badań
Status
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)
SECONDARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.
II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.
III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.
IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.
V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.
VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.
EXPLORATORY OBJECTIVES:
I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:
Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.
III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.
ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Anaheim, California, Stany Zjednoczone, 92806
- Kaiser Permanente-Anaheim
-
Auburn, California, Stany Zjednoczone, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Stany Zjednoczone, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Concord, California, Stany Zjednoczone, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Stany Zjednoczone, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Stany Zjednoczone, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Stany Zjednoczone, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Stany Zjednoczone, 90048
- Cedars Sinai Medical Center
-
Ontario, California, Stany Zjednoczone, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Stany Zjednoczone, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Roseville, California, Stany Zjednoczone, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Stany Zjednoczone, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Stany Zjednoczone, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Stany Zjednoczone, 95817
- University of California Davis Comprehensive Cancer Center
-
Torrance, California, Stany Zjednoczone, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Stany Zjednoczone, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Walnut Creek, California, Stany Zjednoczone, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Stany Zjednoczone, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Stany Zjednoczone, 80210
- AdventHealth Porter
-
Littleton, Colorado, Stany Zjednoczone, 80122
- AdventHealth Littleton
-
Parker, Colorado, Stany Zjednoczone, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Stany Zjednoczone, 06102
- Hartford Hospital
-
New Britain, Connecticut, Stany Zjednoczone, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, Stany Zjednoczone, 19958
- Beebe Medical Center
-
Millville, Delaware, Stany Zjednoczone, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Stany Zjednoczone, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stany Zjednoczone, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Stany Zjednoczone, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Stany Zjednoczone, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Stany Zjednoczone, 19971
- Beebe Health Campus
-
-
Florida
-
Jacksonville, Florida, Stany Zjednoczone, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Stany Zjednoczone, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, Stany Zjednoczone, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Stany Zjednoczone, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Stany Zjednoczone, 31404
- Memorial Health University Medical Center
-
Thomasville, Georgia, Stany Zjednoczone, 31792
- Lewis Hall Singletary Oncology Center
-
-
Hawaii
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stany Zjednoczone, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Stany Zjednoczone, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Stany Zjednoczone, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Stany Zjednoczone, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Island Urology
-
Kailua, Hawaii, Stany Zjednoczone, 96734
- Castle Medical Center
-
Lihue, Hawaii, Stany Zjednoczone, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Stany Zjednoczone, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Stany Zjednoczone, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Stany Zjednoczone, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Stany Zjednoczone, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Stany Zjednoczone, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Stany Zjednoczone, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Stany Zjednoczone, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Stany Zjednoczone, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Stany Zjednoczone, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Stany Zjednoczone, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Stany Zjednoczone, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Northwestern University
-
Chicago, Illinois, Stany Zjednoczone, 60612
- University of Illinois
-
Danville, Illinois, Stany Zjednoczone, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stany Zjednoczone, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Carle Physician Group-Effingham
-
Elmhurst, Illinois, Stany Zjednoczone, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, Stany Zjednoczone, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Stany Zjednoczone, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Stany Zjednoczone, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Stany Zjednoczone, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Stany Zjednoczone, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stany Zjednoczone, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Stany Zjednoczone, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Stany Zjednoczone, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Stany Zjednoczone, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Stany Zjednoczone, 61938
- Carle Physician Group-Mattoon/Charleston
-
Naperville, Illinois, Stany Zjednoczone, 60540
- Edward Hospital/Cancer Center
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Stany Zjednoczone, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Stany Zjednoczone, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Stany Zjednoczone, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stany Zjednoczone, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Stany Zjednoczone, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Stany Zjednoczone, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stany Zjednoczone, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Stany Zjednoczone, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Stany Zjednoczone, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Springfield Clinic
-
Springfield, Illinois, Stany Zjednoczone, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
Urbana, Illinois, Stany Zjednoczone, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Stany Zjednoczone, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Stany Zjednoczone, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Ames, Iowa, Stany Zjednoczone, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stany Zjednoczone, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Stany Zjednoczone, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stany Zjednoczone, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Stany Zjednoczone, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Stany Zjednoczone, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Stany Zjednoczone, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Stany Zjednoczone, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Stany Zjednoczone, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Stany Zjednoczone, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Stany Zjednoczone, 04401
- Eastern Maine Medical Center
-
Bath, Maine, Stany Zjednoczone, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Stany Zjednoczone, 04915
- MaineHealth Waldo Hospital
-
Brewer, Maine, Stany Zjednoczone, 04412
- Lafayette Family Cancer Center-EMMC
-
Portland, Maine, Stany Zjednoczone, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Stany Zjednoczone, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Stany Zjednoczone, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Stany Zjednoczone, 04074
- Maine Medical Partners Neurology
-
Scarborough, Maine, Stany Zjednoczone, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Stany Zjednoczone, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Stany Zjednoczone, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, Stany Zjednoczone, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, Stany Zjednoczone, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Stany Zjednoczone, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Stany Zjednoczone, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Stany Zjednoczone, 48503
- Hurley Medical Center
-
Flint, Michigan, Stany Zjednoczone, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49048
- Beacon Kalamazoo
-
Livonia, Michigan, Stany Zjednoczone, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, Stany Zjednoczone, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Stany Zjednoczone, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stany Zjednoczone, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Stany Zjednoczone, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Stany Zjednoczone, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, Stany Zjednoczone, 48093
- Henry Ford Health Warren Hospital
-
West Branch, Michigan, Stany Zjednoczone, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Stany Zjednoczone, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Stany Zjednoczone, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Stany Zjednoczone, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Stany Zjednoczone, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Stany Zjednoczone, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Stany Zjednoczone, 55433
- Mercy Hospital
-
Edina, Minnesota, Stany Zjednoczone, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Stany Zjednoczone, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Stany Zjednoczone, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Stany Zjednoczone, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Stany Zjednoczone, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stany Zjednoczone, 55454
- Health Partners Inc
-
Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stany Zjednoczone, 55102
- United Hospital
-
Stillwater, Minnesota, Stany Zjednoczone, 55082
- Lakeview Hospital
-
-
Mississippi
-
Jackson, Mississippi, Stany Zjednoczone, 39216
- University of Mississippi Medical Center
-
Southhaven, Mississippi, Stany Zjednoczone, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Stany Zjednoczone, 63703
- Saint Francis Medical Center
-
-
Montana
-
Billings, Montana, Stany Zjednoczone, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stany Zjednoczone, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Stany Zjednoczone, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stany Zjednoczone, 59901
- Logan Health Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Stany Zjednoczone, 68123
- Nebraska Medicine-Bellevue
-
Lincoln, Nebraska, Stany Zjednoczone, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Stany Zjednoczone, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Stany Zjednoczone, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Hackensack University Medical Center
-
Livingston, New Jersey, Stany Zjednoczone, 07039
- Saint Barnabas Medical Center
-
Morristown, New Jersey, Stany Zjednoczone, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Stany Zjednoczone, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Rutgers Cancer Institute of New Jersey
-
Pennington, New Jersey, Stany Zjednoczone, 08534
- Capital Health Medical Center-Hopewell
-
Summit, New Jersey, Stany Zjednoczone, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Stany Zjednoczone, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Stany Zjednoczone, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Stany Zjednoczone, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Stany Zjednoczone, 14642
- University of Rochester
-
Syracuse, New York, Stany Zjednoczone, 13210
- State University of New York Upstate Medical University
-
West Islip, New York, Stany Zjednoczone, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Stany Zjednoczone, 28210
- Atrium Health Pineville/LCI-Pineville
-
Concord, North Carolina, Stany Zjednoczone, 28025
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Bismarck, North Dakota, Stany Zjednoczone, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44304
- Summa Health System - Akron Campus
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Stany Zjednoczone, 43214
- Riverside Methodist Hospital
-
Dublin, Ohio, Stany Zjednoczone, 43016
- Dublin Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Stany Zjednoczone, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Stany Zjednoczone, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Stany Zjednoczone, 97015
- Providence Cancer Institute Clackamas Clinic
-
Gresham, Oregon, Stany Zjednoczone, 97030
- Legacy Mount Hood Medical Center
-
Newberg, Oregon, Stany Zjednoczone, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Stany Zjednoczone, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stany Zjednoczone, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Broomall, Pennsylvania, Stany Zjednoczone, 19008
- Crozer-Keystone Regional Cancer Center at Broomall
-
Chadds Ford, Pennsylvania, Stany Zjednoczone, 19317
- Christiana Care Health System-Concord Health Center
-
Lancaster, Pennsylvania, Stany Zjednoczone, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Stany Zjednoczone, 17602
- Lancaster General Hospital
-
Monroeville, Pennsylvania, Stany Zjednoczone, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
- UPMC-Shadyside Hospital
-
West Reading, Pennsylvania, Stany Zjednoczone, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Stany Zjednoczone, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Rock Hill, South Carolina, Stany Zjednoczone, 29730
- Rock Hill Radiation Therapy Center
-
-
South Dakota
-
Pierre, South Dakota, Stany Zjednoczone, 57501
- Avera Cancer Institute at Pierre
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Stany Zjednoczone, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Stany Zjednoczone, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Stany Zjednoczone, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
American Fork, Utah, Stany Zjednoczone, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Stany Zjednoczone, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Stany Zjednoczone, 84321
- Logan Regional Hospital
-
Murray, Utah, Stany Zjednoczone, 84107
- Intermountain Medical Center
-
Ogden, Utah, Stany Zjednoczone, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Stany Zjednoczone, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Stany Zjednoczone, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84143
- LDS Hospital
-
St. George, Utah, Stany Zjednoczone, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, Stany Zjednoczone, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Stany Zjednoczone, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Stany Zjednoczone, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- Inova Schar Cancer Institute
-
Richmond, Virginia, Stany Zjednoczone, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Stany Zjednoczone, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, Stany Zjednoczone, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Stany Zjednoczone, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Wheeling, West Virginia, Stany Zjednoczone, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Burlington, Wisconsin, Stany Zjednoczone, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Germantown, Wisconsin, Stany Zjednoczone, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Stany Zjednoczone, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Stany Zjednoczone, 54311
- Aurora BayCare Medical Center
-
Johnson Creek, Wisconsin, Stany Zjednoczone, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Stany Zjednoczone, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Stany Zjednoczone, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Stany Zjednoczone, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Stany Zjednoczone, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Stany Zjednoczone, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Stany Zjednoczone, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Stany Zjednoczone, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Stany Zjednoczone, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Stany Zjednoczone, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Stany Zjednoczone, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Stany Zjednoczone, 53227
- Aurora West Allis Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
- Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
-
Contrast-enhanced brain MRI within 3 days after surgery
- MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
- 3D pre contrast-enhanced T1 sequences are strongly suggested
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
PRIOR TO STEP 2 REGISTRATION:
-
Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
- Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
-
MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.
- Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
- Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
-
IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)
- Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
-
History/physical examination within 28 days prior to step 2 registration
-
Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration
-
Neurologic function assessment within 28 days prior to step 2 registration
-
Age >= 18 years
-
Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)
-
Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)
-
Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)
-
Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)
-
Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)
-
Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
Exclusion Criteria:
-
Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;
- Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
Current or planned treatment with any other investigational agents for the study cancer
-
Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide
-
On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed
-
Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody
-
History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease
-
Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:
-
Vitiligo
-
Type I diabetes
-
Rheumatoid arthritis and other arthropathies
-
Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)
- Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
-
-
Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded
-
Current or planned therapy with warfarin
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Arm I (radiation therapy, temozolomide)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Inne nazwy:
Ancillary studies Given PO
Inne nazwy:
Undergo radiation therapy
Inne nazwy:
Undergo contrast-enhanced brain MRI
Inne nazwy:
Wear Optune device
Inne nazwy:
|
|
Eksperymentalny: Arm II (radiation therapy, ipilimumab, nivolumab)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Inne nazwy:
Given IV
Inne nazwy:
Ancillary studies Given IV
Inne nazwy:
Undergo radiation therapy
Inne nazwy:
Undergo contrast-enhanced brain MRI
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II)
Ramy czasowe: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
|
Overall Survival (OS) (Phase III)
Ramy czasowe: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
PFS for the Entire Cohort (Phase II/III)
Ramy czasowe: From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Overall Survival at 2 Years
Ramy czasowe: From randomization to two years
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to two years
|
|
Number of Participants by Highest Grade Adverse Event Reported
Ramy czasowe: From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
Ramy czasowe: Baseline and six months
|
The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months. |
Baseline and six months
|
|
Time to Neurocognitive Failure
Ramy czasowe: From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1. |
From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
|
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
Ramy czasowe: Six months
|
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response. |
Six months
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
OS (jeśli badanie zostanie przerwane w fazie II)
Ramy czasowe: Pod koniec II etapu studiów
|
Pod koniec II etapu studiów
|
|
|
Tumor Biomarker Analyses
Ramy czasowe: Up to 4 years
|
Will assess PD-L1 expression and mutational burden expression specifically. |
Up to 4 years
|
|
MGMT Protein Expression
Ramy czasowe: Up to 4 years
|
Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. |
Up to 4 years
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Andrew B Lassman, NRG Oncology
Publikacje i pomocne linki
Publikacje ogólne
- Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233-1234. doi: 10.1093/neuonc/noaa170. No abstract available.
- Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20;43(27):3032-3040. doi: 10.1200/JCO-25-00618. Epub 2025 Aug 8.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory gruczołowe i nabłonkowe
- Glejak
- Nowotwory neuroepitelialne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Glejak
- Aminokwasy, peptydy i białka
- Białka
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Techniki śledcze
- Lecznictwo
- Azole
- Działania farmakologiczne
- Działania i zastosowania chemiczne
- Czynniki biologiczne
- Zjawiska fizyczne
- Dacarbazine
- Triazennes
- Imidazoles
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Specjalne zastosowania chemikaliów
- Techniki chemii, analityczne
- Analiza widma
- Receptory, powierzchnia komórkowa
- Białka błony
- Antygeny
- Antygeny, powierzchnia
- Biomarkery
- Diagnostyczne zastosowania chemikaliów
- Receptory, immunologiczne
- Antygeny, różnicowanie, limfocyt t
- Antygeny, różnicowanie
- Białka immunologiczne
- Kostymulujące i hamujące receptory komórek T
- Temozolomid
- Niwolumab
- Ipilimumab
- Radioterapia
- Promieniowanie
- Spektroskopia rezonansu magnetycznego
- Contrast Media
- Antygen CTLA-4
Inne numery identyfikacyjne badania
- NCI-2020-03404
- U10CA180868 (Grant/umowa NIH USA)
- NCI-2020-03404 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- NRG-BN007 (Inny identyfikator: CTEP)
- NRG-BN007 (Inny identyfikator: NRG Oncology)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .